Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131,160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.
Zhou C, Lu Y, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Chang J, Fang J, Liu Z, Bu L, Qian L, Xu T, Archer V, Hilton M, Zhou M, Zhang L. Zhou C, et al. Among authors: zhang l, zhang y. JTO Clin Res Rep. 2024 Jun 27;5(9):100700. doi: 10.1016/j.jtocrr.2024.100700. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39282663 Free PMC article.
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Yang Y, Min J, Yang N, Yu Q, Cheng Y, Zhao Y, Li M, Chen H, Ren S, Zhou J, Zhuang W, Qin X, Cao L, Yu Y, Zhang J, He J, Feng J, Yu H, Zhang L, Fang W. Yang Y, et al. Among authors: zhang l, zhang j. Signal Transduct Target Ther. 2023 Aug 14;8(1):301. doi: 10.1038/s41392-023-01538-w. Signal Transduct Target Ther. 2023. PMID: 37574511 Free PMC article. Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Duan J, Wu L, Yang K, Zhao J, Zhao Y, Dai X, Li M, Xie Y, Yao Y, Zhao M, Zhou C, Ren X, Liu Z, Pan Y, Li Y, Liu B, Cheng Y, Miao L, Yu Q, Zhang Z, Liu X, Cui J, Zhang Y, Zhang L, Li X, Li X, Shen B, Chen B, Zeng S, Li B, Hu Y, Li L, Wu R, Song Q, Wang J. Duan J, et al. Among authors: zhang l, zhang z, zhang y. J Thorac Oncol. 2024 Feb;19(2):314-324. doi: 10.1016/j.jtho.2023.09.1449. Epub 2023 Sep 28. J Thorac Oncol. 2024. PMID: 37776953 Free article. Clinical Trial.
Measurement of Ultra-High-Energy Diffuse Gamma-Ray Emission of the Galactic Plane from 10 TeV to 1 PeV with LHAASO-KM2A.
Cao Z, Aharonian F, An Q, Axikegu, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Cai JT, Cao Q, Cao WY, Cao Z, Chang J, Chang JF, Chen AM, Chen ES, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen SH, Chen SZ, Chen TL, Chen Y, Cheng N, Cheng YD, Cui MY, Cui SW, Cui XH, Cui YD, Dai BZ, Dai HL, Dai ZG, Danzengluobu, Della Volpe D, Dong XQ, Duan KK, Fan JH, Fan YZ, Fang J, Fang K, Feng CF, Feng L, Feng SH, Feng XT, Feng YL, Gabici S, Gao B, Gao CD, Gao LQ, Gao Q, Gao W, Gao WK, Ge MM, Geng LS, Giacinti G, Gong GH, Gou QB, Gu MH, Guo FL, Guo XL, Guo YQ, Guo YY, Han YA, He HH, He HN, He JY, He XB, He Y, Heller M, Hor YK, Hou BW, Hou C, Hou X, Hu HB, Hu Q, Hu SC, Huang DH, Huang TQ, Huang WJ, Huang XT, Huang XY, Huang Y, Huang ZC, Ji XL, Jia HY, Jia K, Jiang K, Jiang XW, Jiang ZJ, Jin M, Kang MM, Ke T, Kuleshov D, Kurinov K, Li BB, Li C, Li C, Li D, Li F, Li HB, Li HC, Li HY, Li J, Li J, Li J, Li K, Li WL, Li WL, Li XR, Li X, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu H, Liu HD, Liu J, Liu JL, Liu JY, Liu MY, Liu RY, Liu SM, Liu W, Liu Y, Liu YN, Lu R, Luo Q, Lv HK, Ma BQ, Ma LL, Ma XH, Mao JR, Min Z, Mitthumsiri W, Mu HJ, Nan YC, Neronov A, Ou ZW, Pang B… See abstract for full author list ➔ Cao Z, et al. Among authors: zhang l, zhang hm, zhang r, zhang f, zhang sr, zhang jl, zhang bb, zhang pp, zhang ss, zhang pf, zhang xp, zhang sb, zhang lx, zhang yf, zhang x, zhang hy, zhang y. Phys Rev Lett. 2023 Oct 13;131(15):151001. doi: 10.1103/PhysRevLett.131.151001. Phys Rev Lett. 2023. PMID: 37897763
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
Zhao S, Ma Y, Liu L, Fang J, Ma H, Feng G, Xie B, Zeng S, Chang J, Ren J, Zhang Y, Xi N, Zhuang Y, Jiang Y, Zhang Q, Kang N, Zhang L, Zhao H. Zhao S, et al. Among authors: zhang l, zhang q, zhang y. Lung Cancer. 2024 Feb;188:107468. doi: 10.1016/j.lungcan.2024.107468. Epub 2024 Jan 3. Lung Cancer. 2024. PMID: 38181454 Clinical Trial.
Prognostic Significance of Hyponatremia in Acute Intracerebral Hemorrhage: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial Studies.
Carcel C, Sato S, Zheng D, Heeley E, Arima H, Yang J, Wu G, Chen G, Zhang S, Delcourt C, Lavados P, Robinson T, Lindley RI, Wang X, Chalmers J, Anderson CS; Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 Investigators. Carcel C, et al. Crit Care Med. 2016 Jul;44(7):1388-94. doi: 10.1097/CCM.0000000000001628. Crit Care Med. 2016. PMID: 26958746 Clinical Trial.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: zhang t, zhang h, zhang y. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Constraints on Heavy Decaying Dark Matter from 570 Days of LHAASO Observations.
Cao Z, Aharonian F, An Q, Axikegu, Bai LX, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Cai JT, Cao Z, Chang J, Chang JF, Chen ES, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen SH, Chen SZ, Chen TL, Chen Y, Cheng HL, Cheng N, Cheng YD, Cui SW, Cui XH, Cui YD, D'Ettorre Piazzoli B, Dai BZ, Dai HL, Dai ZG, Danzengluobu, Della Volpe D, Duan KK, Fan JH, Fan YZ, Fan ZX, Fang J, Fang K, Feng CF, Feng L, Feng SH, Feng XT, Feng YL, Gao B, Gao CD, Gao LQ, Gao Q, Gao W, Gao WK, Ge MM, Geng LS, Gong GH, Gou QB, Gu MH, Guo FL, Guo JG, Guo XL, Guo YQ, Guo YY, Han YA, He HH, He HN, He SL, He XB, He Y, Heller M, Hor YK, Hou C, Hou X, Hu HB, Hu Q, Hu S, Hu SC, Hu XJ, Huang DH, Huang WH, Huang XT, Huang XY, Huang Y, Huang ZC, Ji XL, Jia HY, Jia K, Jiang K, Jiang ZJ, Jin M, Kang MM, Ke T, Kuleshov D, Levochkin K, Li BB, Li C, Li C, Li F, Li HB, Li HC, Li HY, Li J, Li J, Li J, Li K, Li WL, Li XR, Li X, Li X, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu H, Liu HD, Liu J, Liu JL, Liu JS, Liu JY, Liu MY, Liu RY, Liu SM, Liu W, Liu Y, Liu YN, Long WJ, Lu R, Luo Q, Lv HK, Ma BQ, Ma LL, Ma XH, Mao JR, Masood A, Min Z, Mitthumsiri W, Nan YC, Ou ZW, Pang BY, Pattarakijwanic… See abstract for full author list ➔ Cao Z, et al. Among authors: zhang l, zhang hm, zhang r, zhang f, zhang sr, zhang jl, zhang bb, zhang pp, zhang ss, zhang pf, zhang xp, zhang sb, zhang lx, zhang yf, zhang yl, zhang x, zhang hy, zhang y. Phys Rev Lett. 2022 Dec 23;129(26):261103. doi: 10.1103/PhysRevLett.129.261103. Phys Rev Lett. 2022. PMID: 36608208
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, Zhang Y, Wan Y, Li W, Song W, Wang ZM, Li B, Xia M, Yang Y, Fang W, Huang Y, Zhang L. Zhao Y, et al. Among authors: zhang l, zhang w, zhang y. EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37593227 Free PMC article.
131,160 results
You have reached the last available page of results. Please see the User Guide for more information.